Phase
Condition
Joint Injuries
Musculoskeletal Diseases
Bone Diseases
Treatment
TS-152
Clinical Study ID
Ages > 20 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
At visit1(-4 weeks), Subject must be fully informed about the study and must obtainwritten informed consent from the subject himself.
At Visit2(0 week), Subjects must have completed the previous study (TS152-3000-JA orTS152-3001-JA) ,and must have completed all evaluations required at the follow-upvisit.
etc.
Exclusion
Exclusion Criteria:
Subjects who had serious adverse drug reactions in the previous study.
At Visit1(-4 weeks) or Visit2 (0 week), Subjects who have not recovered fromclinically important adverse events.
etc.
Study Design
Connect with a study center
Taisho Pharmaceutical Co., Ltd selected site
Tokyo,
JapanSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.